Lacosamide information

Lacosamide
Clinical data
Trade names	Vimpat
Other names	(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide
AHFS/Drugs.com	Monograph
MedlinePlus	a609028
License data	EU EMA: by INN; US DailyMed: Lacosamide;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth, intravenous
ATC code	N03AX18 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only); US: Schedule V; EU: Rx-only;
Pharmacokinetic data
Bioavailability	High
Elimination half-life	13 hours
Excretion	Kidney
Identifiers
	IUPAC name N2-acetyl-N-benzyl-D-homoserinamide;
CAS Number	175481-36-4 ;
PubChem CID	219078;
IUPHAR/BPS	7472;
ChemSpider	189902 ;
UNII	563KS2PQY5;
KEGG	D07299 ;
ChEMBL	ChEMBL58323 ;
CompTox Dashboard (EPA)	DTXSID1057666 ;
ECHA InfoCard	100.112.805
Chemical and physical data
Formula	C13H18N2O3
Molar mass	250.298 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@@H](C(=O)NCc1ccccc1)COC)C;
	InChI InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1 ; Key:VPPJLAIAVCUEMN-GFCCVEGCSA-N ;
	(what is this?) (verify)

Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.^[2] It is used by mouth or intravenously.^[2]

It is available as a generic medication.^[4]^[5]

^ Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.
^ ^a ^b ^c "Vimpat- lacosamide tablet, film coated VIMPAT- lacosamide kit VIMPAT- lacosamide injection VIMPAT- lacosamide solution". DailyMed. December 13, 2021. Archived from the original on March 25, 2022. Retrieved March 24, 2022.
^ "Lacosamide Adroiq". Union Register of medicinal products. June 1, 2023. Retrieved June 6, 2023.
^ "Drugs@FDA: Lacosamide". U.S. Food and Drug Administration (FDA). Archived from the original on March 25, 2022. Retrieved March 24, 2022.
^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). March 3, 2023. Archived from the original on June 30, 2023. Retrieved June 30, 2023.

[1] Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.

[Vimpat_FDA_label-2] "Vimpat- lacosamide tablet, film coated VIMPAT- lacosamide kit VIMPAT- lacosamide injection VIMPAT- lacosamide solution". DailyMed. December 13, 2021. Archived from the original on March 25, 2022. Retrieved March 24, 2022.

[3] "Lacosamide Adroiq". Union Register of medicinal products. June 1, 2023. Retrieved June 6, 2023.

[4] "Drugs@FDA: Lacosamide". U.S. Food and Drug Administration (FDA). Archived from the original on March 25, 2022. Retrieved March 24, 2022.

[5] "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). March 3, 2023. Archived from the original on June 30, 2023. Retrieved June 30, 2023.

Lacosamide information

and 26 Related for: Lacosamide information

Lacosamide

Peripheral neuropathy

Cocaine

Brazilian Controlled Drugs and Substances Act

Ketamine

Epilepsy and pregnancy

Daiichi Sankyo

Benzylamine

Fentanyl

Gabapentin

Bedinvetmab

Analgesic

Naproxen

Tramadol

Paracetamol

Amlodipine

Cholesterol

Promethazine

Ketorolac

Morphine

Topiramate

Chlorphenamine

Thiazide

Lamotrigine

Cannabis

Anticonvulsant